Tocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Release Syndrome.

Autor:	van Kraaij TD; Department of Pulmonology, Zuyderland Medical Center, Heerlen-Sittard, the Netherlands., Mostard RL; Department of Pulmonology, Zuyderland Medical Center, Heerlen-Sittard, the Netherlands., Ramiro S; Department of Rheumatology, Zuyderland Medical Center, Heerlen-Sittard, the Netherlands.; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands., Magro Checa C; Department of Rheumatology, Zuyderland Medical Center, Heerlen-Sittard, the Netherlands., van Dongen CM; Department of Rheumatology, Zuyderland Medical Center, Heerlen-Sittard, the Netherlands., van Haren EH; Department of Pulmonology, Zuyderland Medical Center, Heerlen-Sittard, the Netherlands., Buijs J; Department of Internal Medicine, Zuyderland Medical Center, Heerlen-Sittard, the Netherlands., Landewé RB; Department of Rheumatology, Zuyderland Medical Center, Heerlen-Sittard, the Netherlands.; Department of Rheumatology, Amsterdam University Medical Center (ARC), Amsterdam, the Netherlands.
Jazyk:	angličtina
Zdroj:	European journal of case reports in internal medicine [Eur J Case Rep Intern Med] 2020 Apr 22; Vol. 7 (5), pp. 001675. Date of Electronic Publication: 2020 Apr 22 (Print Publication: 2020).
DOI:	10.12890/2020_001675
Abstrakt:	Younger patients with COVID-19 may experience an exaggerated immune response to SARS-CoV-2 infection and develop cytokine release syndrome (CRS), which may be life threatening. There is no proven antiviral therapy for COVID-19 so far, but profound immunosuppression has recently been suggested as a treatment for COVID-19-associated CRS. We present a case of life-threatening CRS caused by COVID-19 infection with a favourable response to immunosuppressive therapy with tocilizumab (TCZ). The rapid clinical and biochemical improvement following TCZ administration suggests that treatment with immunotherapy can be life-saving in selected patients with COVID-19-induced CRS. Learning Points: Cytokine release syndrome may cause sudden and potentially life-threatening clinical deterioration in COVID-19 pneumonia, particularly in younger patients.Immunosuppressive therapy may provide important additional therapeutic benefit in these patients.Tocilizumab, a specific IL-6 inhibitor, led to dramatic clinical improvement in a young patient with severe COVID-19-associated cytokine release syndrome. Competing Interests: Conflicts of Interests: The Authors declare that there are no competing interests. (© EFIM 2020.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu